Psoriasis is a chronic, inflammatory, multisystem disease that affects up to 3.2% of the US
population. This guideline addresses important clinical questions that arise in psoriasis …

Exposure to certain drugs can elicit an induction or exacerbation of psoriasis. Although well-
conducted systematic studies on drug-related psoriasis are mostly lacking, traditionally …

Background Biological therapy is currently widely used to treat IBD. Infliximab, adalimumab
and golimumab are currently licensed anti‐TNF therapies. Biosimilar anti‐TNF monoclonal …

The treatment of inflammatory bowel disease (IBD)—ulcerative colitis (UC) and Crohn's
disease (CD)—has evolved beyond surgery with the introduction of biologic agents …

Tumor necrosis factor α (TNF-α)-targeted therapies have expanded the therapeutic options
for patients with inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriasis, and …

Introduction: Biological drugs are therapies designed to target a specific molecule of the
immune system that have been linked with the development of autoimmune diseases. Areas …

Abstract Background and Aims Epidemiological studies have established an association
between psoriasis and inflammatory bowel disease [IBD], ie ulcerative colitis [UC] and …

Background Biological agents that contain substances affecting the immune system are
increasingly being used to treat chronic inflammatory systemic diseases. Aside from the …

The ENEIDA registry, promoted by the Spanish Working Group on Crohn's Disease and
Ulcerative Colitis (GETECCU), was created in 2005 by a group of gastroenterologists …

Background Tumor necrosis factor-α (TNF-α) inhibitor (TNFI)-induced psoriasis remains
poorly understood despite having been described 15 years ago. As TNFIs often provide life …